Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single
and multiple administration of KHK7580 for secondary hyperparathyroidism in patients
receiving hemodialysis
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.